ID

23543

Description

Responsible Party: Prof. Dr. Wolf Lagrèze, Prof. Dr. med., University Eye Hospital, Freiburg ClinicalTrials.gov Identifier: NCT01962571 History of Changes Other Study ID Numbers: P000053 2013-002515-10 ( EudraCT Number ) DRKS00005298 ( Registry Identifier: German Clinical Trials Register (DRKS) ) 01KG1306 ( Other Grant/Funding Number: Federal Ministry of Education and Research ) Study First Received: September 30, 2013 Last Updated: October 24, 2016 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial (TONE) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01962571

Link

https://clinicaltrials.gov/ct2/show/NCT01962571

Keywords

Versions (1)
  1. 7/8/17 7/8/17 -
Uploaded on

July 8, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Optic Neuritis NCT01962571 DRKS00005298

English

Eligibility Optic Neuritis NCT01962571 DRKS00005298

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
1. Written informed consent obtained according to international guidelines and local laws
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
2. Male and female patients aged ≥ 18 to ≤ 50 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
3. Patients with ON
Description

Optic Neuritis

Data type

boolean

Alias
UMLS CUI [1]
C0029134
4. First symptoms of ON ≤ 10 days prior to the first administration of investigational product
Description

Onset of Symptoms

Data type

boolean

Alias
UMLS CUI [1]
C0277793
5. High contrast visual acuity (HCVA) of ≤ 0.5 (decimal system)
Description

High contrast visual acuity

Data type

boolean

Alias
UMLS CUI [1]
C0042812
6. Adequate OCT measurements available
Description

OCT measurements

Data type

boolean

Alias
UMLS CUI [1]
C0523800
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
0. Healthy Volunteers
Description

Control Group

Data type

boolean

Alias
UMLS CUI [1]
C0009932
1. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
Description

Capacity

Data type

boolean

Alias
UMLS CUI [1]
C1516240
2. Simultaneous participation in another interventional trial which could interfere with this trial and/or participation in a clinical trial within the last 3 months before enrolment in this trial
Description

Study Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
3. Refractive anomalies: Hyperopia > 5 dpt, myopia < -7 dpt, astigmatism > 3 dpt
Description

Refractive Errors

Data type

boolean

Alias
UMLS CUI [1]
C0034951
4. Media opacity
Description

Media opacity

Data type

boolean

Alias
UMLS CUI [1]
C0010038
5. Severe papillitis
Description

Papillitis

Data type

boolean

Alias
UMLS CUI [1]
C2881208
6. Previous ON
Description

Previous ON

Data type

boolean

Alias
UMLS CUI [1,1]
C0029134
UMLS CUI [1,2]
C0205156
7. Any other optic nerve and retinal disease
Description

Optic nerve and retinal disease

Data type

boolean

Alias
UMLS CUI [1]
C0029132
UMLS CUI [2]
C0035309
8. Pre-existing MS or any other neurological disease
Description

MS or any other neurological disease

Data type

boolean

Alias
UMLS CUI [1]
C0026769
UMLS CUI [2]
C0027765
9. Congenital diseases: - thrombophilia - phenylketonuria
Description

Thrombophilia, phenylketonuria

Data type

boolean

Alias
UMLS CUI [1]
C0398623
UMLS CUI [2]
C0031485
10. Acquired diseases: - autoimmune diseases, - cardiovascular diseases, - diabetes mellitus, - uncontrolled hypertension (with blood pressure > 140 / 90 mm Hg (cf. chapter 7.7.5)), - any malignancy, - epilepsy, - known tuberculosis with ongoing or unknown activity, - acute gastrointestinal ulceration within the last 3 months prior to randomisation, - acute viral, bacterial or fungal infection, - known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus, - history of colitis ulcerosa, diverticulitis, or acute enteroanastomosis, - known osteoporosis, - history of thromboembolic events, - elevated haemoglobin level (>17 g/dl in men or >15 g/dl in women) - polycythaemia - any other significant illness potentially interfering with any trial assessment or trial treatment
Description

Comorbidity

Data type

boolean

Alias
UMLS CUI [1]
C0009488
11. Performing semi-professional or professional sporting activities or physical training
Description

Sporting activities

Data type

boolean

Alias
UMLS CUI [1]
C0577513
12. Pre-treatment with corticosteroids in the last 30 days prior to the onset of optic neuritis
Description

Corticosteroids

Data type

boolean

Alias
UMLS CUI [1]
C0001617
13. Pre-treatment with EPO
Description

EPO

Data type

boolean

Alias
UMLS CUI [1]
C0033567
14. Known or persistent abuse of medication, drugs or alcohol
Description

Substance Use Disorder

Data type

boolean

Alias
UMLS CUI [1]
C0038586
15. Active immunization within 2 weeks prior to randomisation
Description

Vaccination

Data type

boolean

Alias
UMLS CUI [1]
C0042196
16. Significant surgery within 4 weeks prior to randomisation
Description

Surgery

Data type

boolean

Alias
UMLS CUI [1]
C0543467
17. Blood donation or bloodletting within 4 weeks prior to screening
Description

Blood donation

Data type

boolean

Alias
UMLS CUI [1]
C0005794
18. Pre-treatment with immunosuppressive or immunomodulatory agents
Description

Immunosuppression

Data type

boolean

Alias
UMLS CUI [1]
C0021079
19. Persons who are in a relationship of dependence/employment with the sponsor or the investigator
Description

Relationship

Data type

boolean

Alias
UMLS CUI [1]
C0015608
This section concerns only female patients who are able to have a child: 20. Current or planned pregnancy; nursing period within 3 months from investigational product administration
Description

Gynaecological Status

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
This section concerns only female patients who are able to have a child: 21. Unwillingness to use one of the following safe combination methods of contraception within 3 months from investigational product administration to achieve a PEARL index of <1: female condom, diaphragm or coil, each used in combination with a spermicide; hormonal intra-uterine device or hormonal contraception in combination with a mechanical method of contraception
Description

Contraceptive Methods

Data type

boolean

Alias
UMLS CUI [1]
C0700589
Back to the top of the page

Similar models

Eligibility Optic Neuritis NCT01962571 DRKS00005298

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
Informed Consent
Item
1. Written informed consent obtained according to international guidelines and local laws
boolean
C0021430 (UMLS CUI [1])
Age
Item
2. Male and female patients aged ≥ 18 to ≤ 50 years
boolean
C0001779 (UMLS CUI [1])
Optic Neuritis
Item
3. Patients with ON
boolean
C0029134 (UMLS CUI [1])
Onset of Symptoms
Item
4. First symptoms of ON ≤ 10 days prior to the first administration of investigational product
boolean
C0277793 (UMLS CUI [1])
High contrast visual acuity
Item
5. High contrast visual acuity (HCVA) of ≤ 0.5 (decimal system)
boolean
C0042812 (UMLS CUI [1])
OCT measurements
Item
6. Adequate OCT measurements available
boolean
C0523800 (UMLS CUI [1])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
Control Group
Item
0. Healthy Volunteers
boolean
C0009932 (UMLS CUI [1])
Capacity
Item
1. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
boolean
C1516240 (UMLS CUI [1])
Study Participation Status
Item
2. Simultaneous participation in another interventional trial which could interfere with this trial and/or participation in a clinical trial within the last 3 months before enrolment in this trial
boolean
C2348568 (UMLS CUI [1])
Refractive Errors
Item
3. Refractive anomalies: Hyperopia > 5 dpt, myopia < -7 dpt, astigmatism > 3 dpt
boolean
C0034951 (UMLS CUI [1])
Media opacity
Item
4. Media opacity
boolean
C0010038 (UMLS CUI [1])
Papillitis
Item
5. Severe papillitis
boolean
C2881208 (UMLS CUI [1])
Previous ON
Item
6. Previous ON
boolean
C0029134 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Optic nerve and retinal disease
Item
7. Any other optic nerve and retinal disease
boolean
C0029132 (UMLS CUI [1])
C0035309 (UMLS CUI [2])
MS or any other neurological disease
Item
8. Pre-existing MS or any other neurological disease
boolean
C0026769 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
Thrombophilia, phenylketonuria
Item
9. Congenital diseases: - thrombophilia - phenylketonuria
boolean
C0398623 (UMLS CUI [1])
C0031485 (UMLS CUI [2])
Comorbidity
Item
10. Acquired diseases: - autoimmune diseases, - cardiovascular diseases, - diabetes mellitus, - uncontrolled hypertension (with blood pressure > 140 / 90 mm Hg (cf. chapter 7.7.5)), - any malignancy, - epilepsy, - known tuberculosis with ongoing or unknown activity, - acute gastrointestinal ulceration within the last 3 months prior to randomisation, - acute viral, bacterial or fungal infection, - known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus, - history of colitis ulcerosa, diverticulitis, or acute enteroanastomosis, - known osteoporosis, - history of thromboembolic events, - elevated haemoglobin level (>17 g/dl in men or >15 g/dl in women) - polycythaemia - any other significant illness potentially interfering with any trial assessment or trial treatment
boolean
C0009488 (UMLS CUI [1])
Sporting activities
Item
11. Performing semi-professional or professional sporting activities or physical training
boolean
C0577513 (UMLS CUI [1])
Corticosteroids
Item
12. Pre-treatment with corticosteroids in the last 30 days prior to the onset of optic neuritis
boolean
C0001617 (UMLS CUI [1])
EPO
Item
13. Pre-treatment with EPO
boolean
C0033567 (UMLS CUI [1])
Substance Use Disorder
Item
14. Known or persistent abuse of medication, drugs or alcohol
boolean
C0038586 (UMLS CUI [1])
Vaccination
Item
15. Active immunization within 2 weeks prior to randomisation
boolean
C0042196 (UMLS CUI [1])
Surgery
Item
16. Significant surgery within 4 weeks prior to randomisation
boolean
C0543467 (UMLS CUI [1])
Blood donation
Item
17. Blood donation or bloodletting within 4 weeks prior to screening
boolean
C0005794 (UMLS CUI [1])
Immunosuppression
Item
18. Pre-treatment with immunosuppressive or immunomodulatory agents
boolean
C0021079 (UMLS CUI [1])
Relationship
Item
19. Persons who are in a relationship of dependence/employment with the sponsor or the investigator
boolean
C0015608 (UMLS CUI [1])
Gynaecological Status
Item
This section concerns only female patients who are able to have a child: 20. Current or planned pregnancy; nursing period within 3 months from investigational product administration
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Contraceptive Methods
Item
This section concerns only female patients who are able to have a child: 21. Unwillingness to use one of the following safe combination methods of contraception within 3 months from investigational product administration to achieve a PEARL index of <1: female condom, diaphragm or coil, each used in combination with a spermicide; hormonal intra-uterine device or hormonal contraception in combination with a mechanical method of contraception
boolean
C0700589 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial